Angiosarcomas Treatment Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022-2027

Report Code: HCR 0930 Report Format: PDF + Excel

Angiosarcomas Treatment Market Overview

Angiosarcomas Treatment Market Size is estimated to reach $970.4 million by 2027. Furthermore, it is poised to grow at a CAGR of 5.9% over the forecast period of 2022-2027. The growing prevalence of cancer in the world surges the growth of the angiosarcomas treatment market. According to a research study published by National Center for Biotechnology Information (NCBI), the survival rate of patients with angiosarcomas after liver transplantation the 12-month survival rate was 24% and the 24-month mortality rate was 100%. Owing to the high fatality rate of this disease various research organizations and key market players focus on the development of new innovative solutions for diagnosis and cure. For instance, in June 2022, the Food and Drug Administration granted accelerated approval to dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) for the treatment of adult and pediatric patients of 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. Such global demand for diagnosis and treatments such as pneumothorax treatment and the availability of new drugs and treatments drive the growth of the Angiosarcomas Treatment Industry over the forecast period 2022-2027.

Angiosarcomas Treatment Market Report Coverage

The “Angiosarcomas Treatment Market Forecast (2022-2027)" by Industry ARC, covers an in-depth analysis of the following segments in the Angiosarcomas Treatment Market.

by Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Pneumothorax Treatment, Immunohistochemistry and Others.
by Location of Instigation: Hemangiosarcoma and Lymphangiosarcoma.
by End-users: Hospitals & Clinics, Ambulatory Care Centers, Specialised Clinics and Others.
by Geography: North America (the U.S., Canada and Mexico), Europe (Germany, United Kingdom (UK), France, Italy, Spain, Russia and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia and New Zealand and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of the World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America held a dominant market share in the year 2021, owing to the best healthcare facilities and high funding for cancer research surge growth of the Angiosarcomas Treatment Market Size.
  • The Angiosarcomas Treatment Market is predicted to increase owing to the growing geriatric population and the high prevalence of cancer around the world fueling the growth of the Angiosarcomas Treatment Market.
  • However, the low availability of skilled healthcare workers may limit Angiosarcomas Treatment Industry growth over the forecast period 2022-2027.
  • A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Angiosarcomas Treatment Market Report.

Angiosarcomas Treatment Market: Market Share (%) by region, 2021

Angiosarcomas Treatment Market

For More Details On this report - Request For Sample

Angiosarcomas Treatment Market Segment Analysis - by Treatment

Angiosarcomas Treatment Market based on treatment can be further segmented into Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Pneumothorax Treatment, Immunohistochemistry and Others. The Surgery segment held a dominant market share in the year 2021. This is owing to the growing demand for biopsies to investigate types of cancer. It also helps in proper diagnosis and treatment and play important role in various types of cancer. According to cancer statistics, in 2021 by the American Cancer Society more than 1 million biopsies performed in the United States. Owing to the global prevalence of cancer the high demand for cancer surgeries is reported in the past several years. According to a research paper published in the Lancet in January 2021, the indication for surgery of cancer will increase by 5 million procedures (52%) between 2018 (90,65,000) and 2040 (1,38,21,000). Such growing demand for cancer surgery drives the growth of the Angiosarcomas Treatment Market Share.

However, Targeted therapy is estimated to grow with the fastest CAGR of 6.3% over the forecast period 2022-2027. This is owing to the attribute of targeted therapy which directly attacks cancer cells, for example, Pazopanib blocks several cell enzymes called tyrosine kinases that are important for cell growth and survival. It may be used to treat certain advanced soft tissue sarcomas that have not responded to chemotherapy. As chemotherapy offered a 30% success rate, targeted therapy provides up to 80% success rate in some cases. Owing to such attributes of targeted therapies more people adopt them. Such growing popularity of targeted therapy due to its effectiveness fuels the growth of the Angiosarcomas Treatment Market Share over the forecast period 2022-2027.

Angiosarcomas Treatment Market Segment Analysis - by End-users

Angiosarcomas Treatment Market based on the end users can be further segmented into Hospitals & Clinics, Ambulatory Care Centers, Specialised Clinics and Others. The hospital & clinics segment held a dominant market share in the year 2021. This is owing to the growing admission of cancer patients for diagnosis and treatment of cancer in hospitals. According to a research paper published in Nature in November 2021, the study of cancer patients visiting the emergency department (ED) from 2015 to 2019 in Korea found that cancer-related ED visits accounted for 3.1% of all ED visits, with 1.37 million cases over five years. Such a growing number of hospital visits for cancer-related treatments such as pneumothorax treatment, immunohistochemistry and others drive the growth of the Angiosarcomas Treatment Market Share.

However, Ambulatory Care Centers are estimated to grow with the fastest CAGR of 6.1% over the forecast period 2022-2027 owing to the attributes of ambulatory care centers which provide patients with their inpatient chemotherapy regimens and supportive care delivered in outpatient service. Where instead of spending the night in an inpatient bed, patients stay at a nearby hotel or their home while receiving daily treatments and supporting care in ambulatory care facilities. Owing to such facilities most peoples prefer ambulatory care centers rather than long stays at hospitals. Such growing popularity of ambulatory care centers for the treatment of various cancer fuels the growth of the Angiosarcomas Treatment Market share over the forecast period 2022-2027.

Angiosarcomas Treatment Market Segment Analysis - by Geography              

North America held a dominant market share of 34% in the year 2021. This is owing to developed healthcare infrastructure and favorable government policies for research and development of new drugs and treatments. According to National Cancer Institute, the budget for cancer research was increased by 99.3 million (1.6%) from 2020 to 2021. Also, the cases of angiosarcomas along with lymphedema and syncope are increasing in this region. In the United States, one case of angiosarcoma is diagnosed annually for every million persons. Approximately 1% to 2% of all sarcomas are angiosarcomas. Such growing cases of angiosarcomas with lymphedema and government support for research and development of new innovative drugs and treatments drive the growth of the Angiosarcomas Treatment Market Size in this region.

Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is owing to the growing rate of the aging population and the high prevalence of cancer in the elderly population. As it is mostly found in people with age 70 and above and most of the Asia-pacific population is shifting towards old age driving the growth of the angiosarcomas market. According to the World Bank, the total population of south Asia with and above 65 years of age is 11,86,58,106 in 2021. Such a growing elderly population and high chances of cancer in the elderly population fuel growth of the Angiosarcomas Treatment Market Size over the forecast period 2022-2027.

Angiosarcomas Treatment Market Drivers

Growing Risk of Cancer in Geriatric Population Drive Market Growth.

The risk of cancer is high in the geriatric population. According to Union for International Cancer Control (UICC), there are currently over 703 million people worldwide above the age of 65 years, representing 9.1% of the global population. Estimates suggest that this proportion will rise to 15.9% (1.5 billion people) by 2050. Also, according to GLOBOCAN data 2020, more than 50% of people who have cancer are 65 or older. The estimated mortality of all types of cancer in people with age 70 and above is 65,17,865 in 2030, as per UICC. Such growing prevalence and high mortality rate owing to cancer-related disease in the geriatric population drive growth of the Angiosarcomas Treatment Industry over the forecast period 2022-2027.

Growing Funding for Cancer Research Drive Angiosarcomas Treatment Market Growth.

The burden of cancer is increasing rapidly all over the globe. The research published by JAMA Network in December 2021, found that 23.6 million new global cancer cases in 2019 (17.2 million when excluding those with nonmelanoma skin cancer), 10.0 million cancer deaths and an estimated 250 million disability-adjusted life years estimated to be owing to cancer. Such an increasing global burden of cancer surges the need for better diagnostics & treatment. Also, the rapid radiation therapy in breast cancer patients increases the risk of angiosarcomas cancer and drives the growth of the Angiosarcomas Treatment Industry over the forecast period 2022-2027.

Angiosarcomas Treatment Market Challenge

Lack of Proper Diagnostic Facilities in Underdeveloped Countries is Hampering Market Growth

To minimize the severity of cancer and decrease the mortality rate the availability of effective diagnostic techniques plays an important role. In low and middle-income countries owing to lack of proper infrastructure, low investment & funding, unavailability of skilled technicians, high cost of service and many other reasons proper diagnostics is not possible. According to a research article published in Nature in April 2022, there are currently a significant bias in cancer research toward high-income countries (HICs), with little research being done that is important to the needs of low- and middle-income countries (LMICs). However, by 2030, one in eight individuals will receive a cancer diagnosis during their lifetime and almost 75% of all cancer deaths will take place in LMICs. According to the research paper published by the Lancet availability of diagnostics was 19% in basic primary care facilities, 49% in advanced primary care facilities and 68% in hospitals. Such low availability of diagnostics centers and high mortality rate owing to lack of diagnostics may hamper the growth of the Angiosarcomas Treatment Industry growth over the forecast period 2022-2027.

Angiosarcomas Treatment Market Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Angiosarcomas Treatment Market. The top 10 companies in the Angiosarcomas Treatment Market are:

  1. F. Hoffmann La Roche Ltd.
  2. Novartis AG
  3. Bayer AG
  4. GlaxoSmithKline plc.
  5. Sanofi S.A.
  6. Amgen Inc.
  7. Merck & Co. Inc.
  8. AbbiVie Inc.
  9. Eli Lilly and Company
  10. Bausch Health

Recent Developments

  • In April 2022, Novartis announced the U.S. Food and Drug Administration (FDA) has granted commercial licensure approval for its Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facilities to make, test and release commercial Zolgensma, as well as produce gene therapy products for current and future clinical trials. 
  • In October 2021, Amgen announced the successful completion of its previously announced acquisition of Teneobio, Inc. by cash payment of $900 million. The acquisition includes Teneobio's proprietary bispecific and multispecific antibody technologies, which complement Amgen's existing antibody capabilities and BiTE platform and will enable significant acceleration and efficiency in the discovery and development of new molecules.
  • In October 2020, Roche announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older. The approval is primarily based on the results of 2 phase III studies, VIALE-A and VIALE-C. 

Relevant Titles

Cancer Testing/Screening Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0078

Cancer Diagnostics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0195

Cancer Biomarkers Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0194

For more Lifesciences and Healthcare Market reports, please click here

1. Angiosarcomas Treatment Market - Overview
    1.1 Definitions and Scope
2. Angiosarcomas Treatment Market - Executive Summary
3. Angiosarcomas Treatment Market - Comparative Analysis
    3.1 Company Benchmarking – Key Companies
    3.2 Global Financial Analysis – Key Companies
    3.3 Market Share Analysis – Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Angiosarcomas Treatment Market - Start-up Companies Scenario Premium
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Angiosarcomas Treatment Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Angiosarcomas Treatment Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porter's Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Angiosarcomas Treatment Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Angiosarcomas Treatment Market – by Treatment
    8.1 Surgery
    8.2 Radiation Therapy
    8.3 Chemotherapy
    8.4 Targeted Therapy
    8.5 Immunotherapy
    8.6 Pneumothorax Treatment
    8.7 Immunohistochemistry
    8.8 Others
9. Angiosarcomas Treatment Market – by Location of Instigation
    9.1 Hemangiosarcoma
    9.2 Lymphangiosarcoma
10. Angiosarcomas Treatment Market – by End-users
    10.1 Hospitals & Clinics
    10.2 Ambulatory Care Centers
    10.3 Specialised Clinics
    10.4 Others
11. Angiosarcomas Treatment Market - by Geography
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Chile
        11.4.4 Colombia
        11.4.5 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Angiosarcomas Treatment Market - Entropy
13. Angiosarcomas Treatment Market – Industry/Segment Competition Landscape Premium 
    13.1 Market Share Analysis
        13.1.1 Market Share by Region – Key companies
        13.1.2 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Angiosarcomas Treatment Market – Key Company List by Country Premium Premium
15. Angiosarcomas Treatment Market - Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
* "Financials would be provided to private companies on best-efforts basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.